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source of cytokines that weakens the structural integrity of
the aorta in both degenerative and inflammatory
aneurysms.7-17 Such inflammation is present throughout
aneurysm development, and its magnitude is directly
related to aneurysm expansion.9,10,17 This process within
the abdominal aorta appears to be accelerated in certain
individuals, and the extreme end of the inflammatory
spectrum is reached resulting in an inflammatory
aneurysm at a relatively younger age.1-4,6 The predisposi-
tion to and progression of aneurysm inflammation to the
inflammatory variant are unknown, but can be hypothe-
sized to involve genetic or environmental factors.
The human leukocyte antigen (HLA) class II genes
located on chromosome 6 regulate the immune response
and have been identified as genetic determinants in sepa-
rate studies of inflammatory and degenerative
aneurysms.18-22 Although previous studies were useful in
establishing aneurysms as an immune-mediated disease,
the contribution of these genes to the development of
classic inflammatory versus degenerative AAAs has not
been compared in a single study that includes both
aneurysm variants. Furthermore, the disease risk for either
aneurysm variant associated with these genes has not been
determined with quantitative methods.
The objectives of this study were to compare the dis-
tribution of HLA class II genes in separate groups of
patients with classic inflammatory and degenerative AAAs
and to quantify the associated HLA-disease risk for each
aneurysm variant. Such information may provide insight
Abdominal aortic aneurysms (AAAs) are heteroge-
neous with degenerative and inflammatory types recog-
nized as clinically distinct variants.1-5 Inflammatory
aneurysms, as described by Walker et al,1 represent 3% to
10% of all AAAs and have a characteristic thickened aortic
wall and white perianeurysmal inflammation and are often
symptomatic. Although inflammatory aneurysms were
originally designated as a separate clinical and pathologic
entity, recent evidence suggests that they may share a com-
mon pathogenesis with the more familiar atherosclerotic
or degenerative AAA.6
Specifically, studies have demonstrated that a primary
immune response within the aortic wall represents a
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Purpose: Clinically, abdominal aortic aneurysms (AAAs) display a spectrum of inflammation that extends from appar-
ently noninflamed (degenerative) AAAs to the classic inflammatory variant. Genes encoded in the human leukocyte
antigen (HLA) region are important in the development of both variants of AAA; however, their role in progression
to the inflammatory variant is unknown. The purpose of this study was to compare HLA class II genes in patients with
degenerative versus classic inflammatory AAAs and to quantify their impact as disease risk factors.
Methods: Genotypes of the 12 major alleles of the HLA-DR B1 locus were determined in patients with degenerative
(102) and inflammatory (40) AAAs who were compared with controls (118). Univariate and multivariate logistic
regression analyses were used to determine allele distributions and to quantify disease risk.
Results: Distribution of the HLA-DR B1 alleles was nonrandom and similar in both degenerative and inflammatory
AAA groups compared with controls. The B1*02 and B1*04 alleles were enhanced in both degenerative (39.2% vs
25.4%, P = .03; and 35.3% vs 24.6%, P = .08 respectively) and inflammatory (47.5% vs 25.4%, P = .01; and 32.5% vs
24.6%, P = .09, respectively) AAAs compared with controls. The B1*02 and B1*04 alleles were associated with risk for
both degenerative (odds ratio [OR] 2.2; 95% CI, 1.2-4.0; and OR 2.0; 95% CI, 1.1-3.7, respectively) and inflamma-
tory AAAs (OR 3.7; 95% CI, 1.8-8.6; and OR 2.5; 95% CI, 1.1-6.1).
Conclusion: This study demonstrates that identical HLA alleles function as genetic risk factors for both inflammatory
and degenerative AAAs. These results support the concept of a common, immune-mediated pathogenesis for AAAs that
may be modulated by HLA-independent factors. (J Vasc Surg 2001;34:84-9.)
into the genetic predisposition to aneurysm inflammation
and expansion, as well as establish clinically useful genetic
markers of disease risk.
METHODS
Institutional review board approval was granted and
patient consent was obtained for the genotyping and clin-
ical data abstraction necessary for this study.
Genotyping for the 12 major alleles at the HLA-DR
B1 locus was performed in a referred cohort of patients
undergoing elective AAA repair at the Mayo Clinic: 102
patients with degenerative or atherosclerotic aneurysms
and 40 patients with classic inflammatory aneurysms.
Determination of inflammatory versus degenerative AAA
was based on classic, gross operative findings and not his-
tologic examination.1 Any aneurysm in which the determi-
nation of inflammatory versus degenerative based on the
operative description was in question was excluded from
the study. There were no aneurysms classified as indeter-
minate included in the analysis. All patients in the study
were Caucasian, reflecting both the racial distribution of
aneurysms and the geographic location of the study.
For controls, blood samples for HLA genotyping were
taken from 118 ethnically matched individuals. The controls
used in this study were recruited from a program of normal
value donors maintained by the Mayo Clinic and used as a
source of controls in previous studies of HLA genetic
risk.20,23 Because of their participation in this program, the
controls had not been seen for any other clinical problems
and specifically, had no known autoimmune, cardiovascular,
or aortic diseases. Their ages ranged from 20 to 75 years,
and they had not undergone specific imaging of their aortas.
DNA was extracted from whole blood of patients and
control subjects with the DNA Isolation Kit for
Mammalian Blood (Roche Molecular Biochemicals;
Boehringer Mannheim, Indianapolis, Ind) and the
QIAamp Blood Kit (Qiagen, Chatsworth, Calif) according
to manufacturers’ procedures. HLA-DR B1 genotyping
was performed with a Micro SSP HLA DRB kit (One
Lambda, Canoga Park, Calif). Trays provided sequence
specific oligonucleotide primers for the 12 major allelic
variants at the HLA-DR B1 locus. Matched primer pairs
resulted in the amplification of target sequences.
Polymerase chain reaction was performed in a 9600 ther-
mal cycler (PE Biosystems, Foster City, Calif) under the
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following conditions: denaturation at 96°C for 130 sec-
onds, annealing at 63°C for 60 seconds; followed by 9
cycles of 96°C for 10 seconds and 63°C for 60 seconds;
then 20 cycles of 96°C for 10 seconds, 59°C for 50 sec-
onds and 72°C for 30 seconds. Amplified DNA was sepa-
rated by agarose gel electrophoresis and visualized with
ethidium bromide and ultraviolet light.
Clinical characteristics of patients with degenerative
AAAs were compared with those of patients with inflam-
matory AAAs by means of the Wilcoxon rank sum tests for
continuous clinical variables and the χ2 test for discrete
variables.
The frequency of the 12 alleles in inflammatory and
degenerative AAA groups was compared with the control
group initially by means of univariate logistic regression
analysis. Alleles significantly enhanced (P < .05) or
demonstrating a trend toward enhancement (P = .05-.09)
in univariate analysis were identified as possible risk alleles.
Such alleles were then placed into a stepwise logistic
regression analysis to develop a multivariate disease-risk
model reported as odds ratios (ORs) and 95% CIs.
RESULTS
Clinical characteristics. Patients with inflammatory
AAAs were younger (67 vs 72 years, P = .002) and had
larger aneurysms (6.5 vs 5.7 cm, P = .002) than patients
with degenerative AAAs (Table I). In addition, patients
with inflammatory aneurysms were more commonly active
smokers (48% vs 20%, P < .001). Men predominated in
both aneurysm groups, although the proportion of women
tended to be higher in the inflammatory AAA group. A
similar percentage of patients with each aneurysm variant
reported a family history of aortic aneurysms (Table I).
HLA-DR B1 alleles in degenerative AAA. The
B1*02 and B1*04 alleles were enhanced in patients with
degenerative AAAs compared with controls (39.2% vs
25.4%, P = .03; and 35.3% vs 24.6%, P = .08, respectively)
(Table II). In contrast, the B1*01 (17.6% vs 27.1%, P =
.09), B1*08 (6.9% vs 14.4%, P = .07), and B1*14 (2.0% vs
10.2%, P = .02) alleles were diminished in the degenerative
aneurysm group compared with controls. The seven remain-
ing alleles at the DR B1 locus were distributed randomly
between patients with degenerative aneurysms and controls.
HLA-DR B1 alleles in inflammatory aneurysms.
Similar to patients with degenerative AAAs, the B1*02 and
Table I. Clinical characteristics of patients with degenerative and inflammatory AAAs
Characteristic Degenerative AAA (n = 102) Inflammatory AAA (n = 40) P value
Age (y)* 72 (52-88) 67 (42-90) .002
Aneurysm diameter (cm) 5.7 (4.5-9.0) 6.5 (4.0-10.0) .002
Sex (% female) 13 25 .08
Active smoking (%) 20 48 < .001
Pack years smoked* 40 (0-120) 50 (20-99) .92
Family history (%) 19 20 .94
*Median (range).
B1*04 alleles were more frequent in the inflammatory
aneurysm group compared with controls (47.5% vs 25.4%,
P = .01; and 32.5% vs 24.6%, P = .09, respectively) (Table
II). The B1*01, B1*08, and B1*14 alleles also appeared to
be diminished in the inflammatory AAA group compared
with controls, although these distributions did not reach
statistical significance. In contrast to patients with degen-
erative AAAs, the B1*09 allele was enhanced in the inflam-
matory AAA group compared with controls (12.5% vs
3.4%, P = .04) and represented the only divergent allele
between inflammatory and degenerative aneurysm groups.
Multivariate disease risk models. The increased fre-
quency of the B1*02 and B1*04 alleles was the same in
patients with degenerative and inflammatory aneurysms
compared with controls (Fig 1). These alleles were there-
fore identified as primary risk alleles for both aneurysm
variants and entered into multivariate analysis, in which
the B1*02 and B1*04 alleles were found to be indepen-
dently associated with risk for both degenerative and
inflammatory AAAs (Fig 2). Specifically, the B1*02 allele
was associated with inflammatory (OR 3.6; 95% CI, 1.6-
8.6) and degenerative (OR 2.2; 95% CI, 1.2-4.0)
aneurysms. The B1*04 allele was also associated with the
presence of inflammatory (OR 2.5; 95% CI, 1.1-6.1) and
degenerative (OR 2.0; 95% CI, 1.1-4.0) aneurysms. There
were no two-way interactions between these risk alleles in
either aneurysm variant suggesting the OR in a B1*02/04
heterozygous patient to be additive and not exponential.
DISCUSSION
This study establishes genetic similarity within the
HLA class II immune response genes in patients with
degenerative and classic inflammatory AAAs. Specifically,
this study identifies the same genetic risk factors for both
variants of aneurysm and provides quantitative data about
the disease risk associated with these genetic determinants.
Previous studies. These findings confirm the original
study of HLA genes in inflammatory aneurysms that iden-
tified the B1*02 (which includes the B1*15 and B1*16
alleles) and B1*04 alleles as risk determinants.20 In addi-
tion, it corroborates similar findings in groups of Japanese
and African American patients with degenerative
AAAs.21,22 The current study extends previous investiga-
tions by comparing, for the first time, the distribution of
these genes in groups of white patients with degenerative
and inflammatory variants of aneurysm. Furthermore, this
investigation provides new quantitative data about the
actual disease risk for both variants of aneurysm associated
with these genetic factors.
HLA-associated genetic burden. The HLA class II
genetic similarity in patients with degenerative and inflam-
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Fig 1. Univariate logistic regression analysis demonstrating simi-
lar distribution of HLA-DR B1*02 and B1*04 alleles in patients
with degenerative and inflammatory AAAs versus controls. AAA,
Abdominal aortic aneurysm.
Fig 2. Multivariate disease-risk model for identified risk alleles,
HLA-DR B1*02 and B1*04, in patients with inflammatory and
degenerative AAAs. AAA, Abdominal aortic aneurysm. 
Fig 3. Univariate logistic regression analysis demonstrating
divergent distribution of HLA-DR B1*09 allele in patients with
degenerative and inflammatory AAAs versus controls. AAA,
Abdominal aortic aneurysm.
matory aneurysms is underscored by the enhanced B1*02
and *04 alleles in both aneurysm groups (Fig 1).
Although these alleles represent common risk factors for
both variants of aneurysm, the HLA genetic burden
appears to be greater in patients with inflammatory
aneurysms. Specifically, the ORs associated with the
B1*02 and *04 alleles were greater in the inflammatory
aneurysm group, which contained only 40 patients. This
observation supports the premise that immune-related
mechanisms are important in aneurysm pathogenesis and
suggests a direct relationship between the burden of HLA
genetic risk and the severity of aneurysm inflammation
seen clinically.
The divergent distribution of the B1*09 allele in
patients with inflammatory aneurysms compared with
patients with degenerative aneurysms was unexpected (Fig
3). Although this allele is uncommon in the white popu-
lation, it represents the only allele where there was clear
difference between the aneurysm variants. The signifi-
cance of the B1*09 allele cannot be fully explained in this
study but is likely related to HLA genetic burden and spe-
cific progression to the clinically unique inflammatory
aneurysm.
Limitations. The HLA class II immune response
genes were examined only in patients with larger
aneurysms undergoing AAA repair. The role of these
genes as factors in small AAAs and their potential role in
predicting aneurysm expansion or rupture remains to be
determined. In addition, the means to distinguish
between aneurysm variants in this study was based only on
classic operative findings and not histologic evaluation.
This process makes it possible that aneurysms classified
grossly as degenerative or noninflammatory may have had
adventitial inflammation present histologically.
The abdominal aorta was not specifically imaged in the
control group, which made it possible that controls had
AAAs. This possibility is unlikely because the controls
were individuals with no clinically evident cardiovascular
or immune-related disease. Even in such an unlikely 
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case, the HLA-risk of such persons would be the same as
those in the aneurysm groups, and their removal from 
the control group would only increase or strengthen the
reported ORs.
Implications. Despite these limitations, this study
has important implications related to AAA pathogenesis,
risk factor modification, and early aneurysm detection.
Specifically, the finding of genetic similarity between vari-
ants of AAA suggests that HLA-independent factors such
as cigarette smoking and sex predominate in the amplifi-
cation of AAA inflammation.
The new quantitative data from this study identify
patients at increased genetic risk to have degenerative and
inflammatory aneurysms and, therefore, have clinical
importance. Specifically, a more than doubling of the dis-
ease risk for aneurysms in B1*02+ and B1*04+ individuals
is significant enough to consider these genetic markers for
clinical screening purposes. Although this study was not
designed to address specific screening issues, HLA type
can be considered a stable marker of disease risk that does
not change over time. On the basis of the findings of this
study, it may be reasonable to use HLA type to identify
persons (B1*02+ and B1*04+) to be preferentially
screened with ultrasound. Ultrasound screening is cur-
rently more applicable than genetic screening; however, as
the role of these and other genes in aneurysm develop-
ment is clarified, they may become a useful adjunct in early
aneurysm detection and surveillance.
CONCLUSIONS
This study identifies identical HLA alleles that func-
tion as genetic risk factors for both degenerative and
inflammatory AAAs. These quantitative data support the
concept of an immune-mediated pathogenesis common to
both aneurysm variants and establish biomarkers of disease
risk that may be clinically useful. It can be predicted that
HLA-independent factors such as cigarette smoking and
sex predominate in modulating the progression of AAA
inflammation to the classic inflammatory variant.
Table II. Frequencies of 12 major alleles at HLA DR B1 locus in patients with degenerative and inflammatory AAAs
versus controls
HLA-DR B1 allele Degenerative AAA (n = 102), % Inflammatory AAA (n = 40), % Controls (n = 118), % 
*01 (DR 1) 17.6* 20.0 27.1
*02 (DR 2) 39.2* 47.5† 25.4
*03 (DR 3) 23.5 22.5 22.0
*04 (DR 4) 35.3* 32.5† 24.6
*07 (DR 7) 14.7 15.0 19.5
*08 (DR 8) 6.9* 5.0 14.4
*09 (DR 9) 0 12.5† 3.4
*10 (DR 10) 2.9 0 2.5
*11 (DR 11) 18.6 10.0 22.0
*12 (DR 12) 2.9 0 0.8
*13 (DR 13) 26.5 20.0 20.3
*14 (DR 14) 2.0* 0 10.2
*P < .10 degenerative AAAs versus controls.
†P < .10 inflammatory AAAs versus controls.
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Dr B. Timothy Baxter (Omaha, Neb). Have you looked at
MMP9 levels in these patients with standard aneurysms and with
inflammatory aneurysms? Can you give us some information
about whether MMP-9 is just a marker of the degree of inflam-
mation or whether it may be an important marker about growth
rate of aneurysms?
Dr Todd Rasmussen. Good question. To answer it specifi-
cally, we have not looked in these patients at metalloproteinase
levels. I agree that it has never been demonstrated directly that
inflammatory aneurysms expand at a higher rate than degenera-
tive aneurysms, although current smoking as Dr Powell has
demonstrated or active cigarette smoking does accelerate
aneurysm expansion rates and current smokers are more likely to
have inflammatory aneurysms, but we have not looked at metal-
loproteinase levels. 
I think our understanding of these HLA genes is in its infancy
and one limitation of this study is that we only looked at these
genes in patients who had aneurysms large enough to undergo
repair. I think our real understanding will come as we look at
these specific risk factors in large groups of patients with smaller
aneurysms and whether or not these factors, genetic factors, influ-
ence expansion rates or are associated with expansion or even rup-
ture rates.
Dr Gregorio Sicard (St Louis, Mo). Great work. Maybe I
missed it in the presentation, but did you find any difference in
that 19% and 20% of patients who had a family history of
aneurysms?
Dr Rasmussen. No, sir, we did not. The interesting thing is
that although the family history associated with aneurysms is
kind of what got us into looking at these disease-risk genes,
they do not appear to necessarily correlate with positive family
history, which is why we have gone to multivariate disease risk
models to try to quantify what we see, but we did not find a
difference. 
Dr James C. Stanley (Ann Arbor, Mich). One question that
may be posed is whether you examined a different group of con-
trols, namely, those with atherosclerotic aortoiliac, coronary, or
carotid artery occlusive disease. There are many markers now
related to plaque stability and progressive atherosclerosis, such as
C-reactive protein, that are related to inflammatory processes,
DISCUSSION
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and data from these groups may be quite relevant to the patho-
genesis of abdominal aortic aneurysms.
Dr Rasmussen. No, sir, we did not look at controls with
known coronary disease or even athero-occlusive disease of the
aortoiliac segment, which I think is a focus of future research.
Dr Gilbert Upchurch (Ann Arbor, Mich). I guess the question
is, in your screening did you find any alleles that were protective?
Dr Rasmussen. That is a great question and one that we really
relied heavily on Connie Weyand to help us with. We did not in
these smaller groups find protective alleles. However, if you look
at larger groups or combine these groups statistically, there is one
allele, the DR B1-01 allele, that is underrepresented in aneurysm
patients. Therefore, it has a negative association with aneurysms
and is therefore protective. Interestingly, in tissue work we find
that patients with that exact allele are prone to have less inflam-
mation in their aneurysms if you grade it, so it looks like that may
be a protective allele. One last comment on that specific allele is
it is also underrepresented in giant cell arteritis patients, which is
another immune-related arterial disease, so it is also a protective
allele in other inflammatory arterial diseases.
